Drawing for ACUITY SPATIAL GENOMICS

USPTO serial 90806947

ACUITY SPATIAL GENOMICS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
RENNIE, GABRIELLE M
Law office
TMEG LAW OFFICE 106 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ACUITY SPATIAL GENOMICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

GAIL I NEVIUS ABBAS

GAIL I NEVIUS ABBAS PRANGER LAW PC88 GUY PLACE, SUITE 405SAN FRANCISCO, CA 94105UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Biological and chemical reagents for scientific or medical research and kits consisting primarily of reagents for scientific or medical research comprised of oligonucleotides, probes, primers, antibodies, permeabilization solutions, denaturation solutions, fixation reagents, ligation solutions, biochemical buffers, hybridization solutions, imaging solutions, enzymes, fluorescent dyes, and microsphere beads for genomic, transcriptomic, proteomic, or multiomic in situ analysis of biological samples; Biological and chemical reagents for scientific or medical research and kits consisting primarily of reagents for scientific or medical research comprised of oligonucleotides, probes, primers, antibodies, permeabilization solutions, denaturation solutions, fixation reagents, ligation solutions, biochemical buffers, hybridization solutions, imaging solutions, enzymes, fluorescent dyes, and microsphere beads for genomic, transcriptomic, proteomic, or multiomic analysis of individual cells or multiple individual cells; Biological and chemical reagents for scientific or medical research and kits consisting primarily of reagents for scientific or medical research comprised of oligonucleotides, probes, primers, antibodies, permeabilization solutions, denaturation solutions, fixation reagents, ligation solutions, biochemical buffers, hybridization solutions, imaging solutions, enzymes, fluorescent dyes, and microsphere beads for genomic, transcriptomic, proteomic, or multiomic subcellular analysis of biological samplesABANDONED—
009computer hardware; downloadable computer software for performing genomic, transcriptomic, proteomic, or multiomic imaging and in situ analysis of biological samples for scientific or medical research; computer systems comprised of computer hardware and downloadable computer software for performing imaging and analysis of biological samples for scientific or medical research; laboratory equipment and scientific instruments, namely, non-medical imaging devices in the nature of microscopes, fluidics devices in the nature of proportioning pumps, valves, and fluid reservoirs for use with microscopes, microfluidics devices in the nature of proportioning pumps, valves, and fluid reservoirs for use with microscopes, biological sample preparation equipment in the nature of reagent cartridges for housing reagents, and biological sample processing equipment in the nature of cover slips for sample processing, all of the foregoing for performing genomic, transcriptomic, proteomic, or multiomic imaging and in situ analysis of biological samples for scientific or medical research; downloadable computer software for performing genomic, transcriptomic, proteomic, or multiomic imaging and multicellular, single-cell, and subcellular analysis of biological samples for scientific or medical research; laboratory equipment and scientific instruments, namely, non-medical imaging devices in the nature of microscopes, fluidics devices in the nature of proportioning pumps, valves, and fluid reservoirs for use with microscopes, microfluidics devices in the nature of proportioning pumps, valves, and fluid reservoirs for use with microscopes, biological sample preparation equipment in the nature of reagent cartridges for housing reagents, and biological sample processing equipment in the nature of cover slips for sample processing, all of the foregoing for performing genomic, transcriptomic, proteomic, or multiomic imaging and multicellular, single-cell, and subcellular analysis of biological samples for scientific or medical researchABANDONED—
042scientific and medical research services for performing genomic, transcriptomic, proteomic, or multiomic in situ analysis of biological samples; scientific and medical research services for performing genomic, transcriptomic, proteomic, or multiomic single-cell or multicell analysis of biological samples; scientific and medical research services for performing genomic, transcriptomic, proteomic, or multiomic subcellular analysis of biological samples; providing online non-downloadable software for data storage, data management, data analysis, data interpretation, data visualization, and data reporting of genomic, transcriptomic, proteomic, or multiomic analysis of biological samples for scientific or medical research; Providing temporary use of non-downloadable cloud-based software for data storage, data management, data analysis, data interpretation, data visualization, and data reporting of genomic, transcriptomic, proteomic, or multiomic analysis of biological samples for scientific or medical researchABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 22, 2024PC.DPETITION TO DIRECTOR DISMISSED—
Feb 20, 2024MAB4ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION—
Feb 20, 2024OP.TOPPOSITION TERMINATED NO. 999999—
Feb 20, 2024ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Feb 20, 2024OP.SOPPOSITION SUSTAINED NO. 999999—
Feb 16, 2024APETASSIGNED TO PETITION STAFF—
Dec 18, 2023TPDRTEAS PETITION TO DIRECTOR RECEIVED—
Aug 9, 2023OP.IOPPOSITION INSTITUTED NO. 999999—
May 10, 2023ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Apr 11, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 11, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 22, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 9, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 8, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 7, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 7, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 15, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 15, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 15, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 22, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 22, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 28, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 22, 2022DOCKASSIGNED TO EXAMINER—
Sep 13, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 5, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance